CYP3A Activity and Rivaroxaban Serum Concentrations in Russian Patients with Deep Vein Thrombosis

Сычев, Д. А.; Vardanyan, A.V.; Рожков, А. В.; Hachatryan, Edita; Badanyan, A.; Смирнов, В. В.; Ananichuk, Anna; Denisenko, Natalia P.

doi:10.1089/gtmb.2017.0152

Cited by 17 publications

(10 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A correlation was reported between the length of the initial thrombus and the time to total recanalization (P < 0.0001). 26 The DOACs may not be effective enough when the area of thrombus occlusion is large.…”

Section: J O U R N a L P R E -P R O O Fmentioning

confidence: 99%

Outcomes after Rivaroxaban Treatment of Extensive Deep Vein Thrombosis

Fujioka

Kitamura

Shikata

et al. 2022

Annals of Vascular Surgery

View full text Add to dashboard Cite

Section: J O U R N a L P R E -P R O O Fmentioning

confidence: 99%

Outcomes after Rivaroxaban Treatment of Extensive Deep Vein Thrombosis

Fujioka

Kitamura

Shikata

et al. 2022

Annals of Vascular Surgery

View full text Add to dashboard Cite

“…Hal tersebut menjadi dasar pemahaman pengaruh variasi gen pemetabolisme dapat memengaruhi aktivitas enzim pemetabolisme (menjadi pemetabolisme lambat, menengah, atau cepat) sehingga dapat merubah keamanan dan efikasi dari rivaroxaban pada populasi tertentu. 15…”

Section: Farmakodinamik Dan Farmakokinetik Rivaroxabanunclassified

“…Gen CYP3A4 merupakan bagian dari gen sitokrom P450 yang berada pada kromosom 7q22.1. 15 Lebih dari 139 varian CYP3A4 sudah teridentifikasi. CYP3A4*1A merupakan tipe liar/wild type, sedangkan CYP3A4*1B merupakan tipe mutasi -392A>G pada daerah 5'UTR, CYP3A4*1G terletak pada intron 10 gen CYP3A4 yang banyak dipelajari pada populasi Asia.…”

Section: Polimorfisme Cyp3a4 Dan Pengaruhnya Terhadap Kadar Rivaroxabanunclassified

Effect of Gene Polymorphism in Drug-metabolizing Enzyme on Concentration of Rivaroxaban: A Narrative Review

Atmaja

Kristiyani

Rawar

2022

Indones J Clin Pharm

View full text Add to dashboard Cite

Rivaroxaban is an anticoagulant agent that often experience biotransformation in the liver through CYP3A4/5 (18%); CYP2J2 (14%) and CYP independent hydrolytic cleavage (14%). Several studies revealed that Polymorphism in drug-metabolizing enzyme genes can affect the rivaroxaban levels in the body. Therefore, this study aims to review the effect of gene variations of metabolizing enzymes on rivaroxaban concentration in patient’s body. A search using keyword rivaroxaban, polymorphism, CYP3A4, CYP3A5 and CYP2J2 was carried out in Google Scholar. Several studies showed that polymorphisms of metabolizing genes do not have a significant effect on rivaroxaban concentration. There is also a need for comprehensive studies involving all single nucleotide polymorphisms (SNPs) that play a role in the drug’s pharmacokinetics. This is because rivaroxaban is metabolized by several CYP isoenzymes and excreted by different transporters. This still opens the opportunity for further studies on its pharmacogenomic.

show abstract

“…Sychev et al reported a significant correlation between CYP3A activity and rivaroxaban peak and trough levels in patients with deep vein thrombosis [70]. However, no significant correlation between CYP3A activity and treatment parameters in deep vein thrombosis patients treated with rivaroxaban were found [70]. A summary of genetic variants analyzed for rivaroxaban is provided in Table 2.…”

Section: Rivaroxabanmentioning

confidence: 99%

Pharmacogenomics of Novel Direct Oral Anticoagulants: Newly Identified Genes and Genetic Variants

Kanuri

Kreutz

2019

JPM

105

View full text Add to dashboard Cite

Direct oral anticoagulants (DOAC) have shown an upward prescribing trend in recent years due to favorable pharmacokinetics and pharmacodynamics without requirement for routine coagulation monitoring. However, recent studies have documented inter-individual variability in plasma drug levels of DOACs. Pharmacogenomics of DOACs is a relatively new area of research. There is a need to understand the role of pharmacogenomics in the interpatient variability of the four most commonly prescribed DOACs, namely dabigatran, rivaroxaban, apixaban, and edoxaban. We performed an extensive search of recently published research articles including clinical trials and in-vitro studies in PubMed, particularly those focusing on genetic loci, single nucleotide polymorphisms (SNPs), and DNA polymorphisms, and their effect on inter-individual variation of DOACs. Additionally, we also focused on commonly associated drug-drug interactions of DOACs. CES1 and ABCB1 SNPs are the most common documented genetic variants that contribute to alteration in peak and trough levels of dabigatran with demonstrated clinical impact. ABCB1 SNPs are implicated in alteration of plasma drug levels of rivaroxaban and apixaban. Studies conducted with factor Xa, ABCB1, SLCOB1, CYP2C9, and VKORC1 genetic variants did not reveal any significant association with plasma drug levels of edoxaban. Pharmacokinetic drug-drug interactions of dabigatran are mainly mediated by p-glycoprotein. Strong inhibitors and inducers of CYP3A4 and p-glycoprotein should be avoided in patients treated with rivaroxaban, apixaban, and edoxaban. We conclude that some of the inter-individual variability of DOACs can be attributed to alteration of genetic variants of gene loci and drug-drug interactions. Future research should be focused on exploring new genetic variants, their effect, and molecular mechanisms that contribute to alteration of plasma levels of DOACs.

show abstract

CYP3A Activity and Rivaroxaban Serum Concentrations in Russian Patients with Deep Vein Thrombosis

Abstract: The direct link between the initial clot length and time to full recanalization that has been found means that patients with more advanced stages of thrombosis need more time to reach recanalization than their counterparts with a less severe condition.

Cited by 17 publications

References 12 publications

Outcomes after Rivaroxaban Treatment of Extensive Deep Vein Thrombosis

Outcomes after Rivaroxaban Treatment of Extensive Deep Vein Thrombosis

Effect of Gene Polymorphism in Drug-metabolizing Enzyme on Concentration of Rivaroxaban: A Narrative Review

Pharmacogenomics of Novel Direct Oral Anticoagulants: Newly Identified Genes and Genetic Variants

Contact Info

Product

Resources

About